Join to View Full Profile
400 Parnassus AveSan Francisco, CA 94143
Phone+1 415-353-2421
Fax+1 415-353-2467
Dr. Martin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1993 - 1996
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1989 - 1992
Uconn School Of MedicineClass of 1989
Certifications & Licensure
CA State Medical License 1991 - 2026
TX State Medical License 1999 - 2002
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Brian Durie Award International Myelona Foundation, 2023
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer Start of enrollment: 1999 Jan 01
- Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Start of enrollment: 2002 Jan 01
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Start of enrollment: 2004 Sep 01
Publications & Presentations
PubMed
- Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myelo...Cindy Varga, Myra Robinson, James A Davis, Hamza Hashmi, Thomas G Martin
Blood Cancer Journal. 2026-03-20 - Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.Magdalena Corona, Roberto García-Vicente, Adolfo Jesús Saez-Marin, Raquel Ancos-Pintado, Alba Rodríguez-Garcia
Journal for Immunotherapy of Cancer. 2026-03-06 - 4 citationsTalquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.Ajai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, Katja Weisel, María-Victoria Mateos
Blood. 2025-12-11
Press Mentions
FDA Approves New CAR T Cancer Therapy for Form of Multiple MyelomaFebruary 28th, 2022- New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (Cilta-Cel) in Treatment of Heavily Pre-Treated Patients with Multiple MyelomaDecember 12th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
